Skip to main content

A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)

Completed · Phase 2 · NCT03395210

Conditions: Immune Thrombocytopenia

At a glance

Research payments reported, 2025
$49,582
U.S. investigators named
3
Sites paid
6
Planned or actual enrollment
86

About the trial

Sponsor
Principia Biopharma, a Sanofi Company
Tested
Rilzabrutinib (drug)
Dates
Started 2018-03-22; completion 2025-12-11
Results posted
Yes

This was a 2 part (Part A and B) adaptive, open-label, dose-finding study of PRN1008 in patients with ITP who are refractory or relapsed with no available and approved therapeutic options, with a platelet count \<30,000/μL on two counts no sooner than 7 days apart in the 15 days before treatment begins. The dose-finding portion of the study was completed. Part B treatment dose was 400 mg twice daily.

From ClinicalTrials.gov, last updated 2026-02-23. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Sanofi US Services Inc. reported $49,582 in research payments for this study in 2025 (8 payments).

Products named: Wayrilz

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Weill Medical College of Cornell University Attn Joint Clinical Trials Office $34,310
  • The Bleeding and Clotting Disorders Institute $6,365
  • Dana Farber PArtners Cancer Care Inc $3,726
  • Bleeding and Clotting Disorders Ins $2,546
  • Dana Farber Mass General Brigham Ca Care Inc $1,635
  • Bleeding and Clotting Disorders Institute $1,000

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.